Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations

<b>Background/Objectives:</b> Infliximab, ipilimumab, and nivolumab are three monoclonal antibodies that have been associated with hepatotoxicity. Three separate physiologically based pharmacokinetic (PBPK) models were developed in GastroPlus<sup>®</sup> to simulate plasma an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Celeste Vallejo, Cameron Meaney, Lara Clemens, Kyunghee Yang, Viera Lukacova, Haiying Zhou
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Pharmaceutics
Subjects:	physiologically based pharmacokinetic model infliximab ipilimumab nivolumab large molecule hepatic concentration
Online Access:	https://www.mdpi.com/1999-4923/17/3/372
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
by: Jung Sun Kim, et al.
Published: (2025-06-01)

Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven‐Year‐Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review
by: Aziz Eghbali, et al.
Published: (2025-08-01)

Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases
by: Chika Nagahisa, et al.
Published: (2025-08-01)

INFLIXIMAB: HAVE ALL QUESTIONS BEEN ANSWERED FOR 10 YEARS?
by: R M Balabanova, et al.
Published: (2010-03-01)

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
by: Young Kwang Chae, et al.
Published: (2025-08-01)

Nivolumab-induced interstitial lung disease in the patient with melanoma
by: Marcin Morawski, et al.
Published: (2024-02-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease
by: Yoon Zi Kim, et al.
Published: (2025-07-01)

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
by: Joo Hye Song, et al.
Published: (2025-05-01)

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Efficacy and safety of nivolumab in the treatment of relapsed/refractory classical Hodgkin’s lymphoma: Pavlov First Saint Petersburg State Medical University experience
by: K. V. Lepik, et al.
Published: (2019-01-01)

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
by: D. D. Ivanova, et al.
Published: (2024-12-01)

EVALUATION OF EFFICACY AND SAFETY OF COMPLEX TREATMENT WITH INFLIXIMAB AND METHOTREXATE COMPARING WITH METHOTREXATE MONOTHERAPY OF CHILDREN WITH JUVENILE POLYARTICULAR IDIOPATHIC ARTHRITIS
by: V. A. Kel'tsev, et al.
Published: (2012-03-01)

The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
by: Junya Song, et al.
Published: (2024-12-01)

GastroPlus® as simulating/ conducting software for modeling physiologically-based pharmacokinetics &amp; physiologically based biopharmaceutics.
by: Yasir Qasim Almajidi, et al.
Published: (2025-07-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients
by: Mohammed Hadi Al-Osami, et al.
Published: (2018-01-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

DYNAMICS OF CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS AS INFLUENCED BY INFLIXIMAB (REMIKEID) ADMINISTRATION
by: E. S. Zhugrova, et al.
Published: (2014-07-01)

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
by: Omer Faruk Kuzu, et al.
Published: (2025-07-01)

Higher induction and maintenance infliximab trough levels are associated with radiological perianal fistula healing in pediatric patients with Crohn's disease
by: Joonhyuk Son, et al.
Published: (2025-05-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Nivolumab in platinum-refractory unresectable locally advanced squamous cell carcinoma of the head and neck: A case report and literature review
by: M.S. Ruban, et al.
Published: (2025-03-01)

Nivolumab in real-life clinical practice
by: M. A. Lyadova, et al.
Published: (2019-12-01)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
by: Elisa Gozzi, et al.
Published: (2020-05-01)

Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
by: Xinming Lei, et al.
Published: (2024-11-01)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
by: David Anson, et al.
Published: (2019-01-01)

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: Drew M Pardoll, et al.
Published: (2020-10-01)

Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation
by: Chiara Zunino, et al.
Published: (2025-07-01)

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
by: I. M. Marusenko, et al.
Published: (2019-03-01)

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy
by: Yu-ying Lei, et al.
Published: (2025-08-01)

Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study
by: Maral Martin Mildanoglu, et al.
Published: (2025-07-01)

EFFICIENCY OF ANTI-INFLAMMATORY THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS ACCORDING TO THE RESULTS OF A PROSPECTIVE FOLLOW-UP STUDY
by: T. A. Raskina, et al.
Published: (2016-09-01)

Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
by: Sam Plessers, et al.
Published: (2025-01-01)

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
by: Pavlos Msaouel, et al.
Published: (2025-01-01)

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
by: Wei Li, et al.
Published: (2024-10-01)

Current views on the pharmacotherapy of psoriatic arthritis
by: G. G. Taradin, et al.
Published: (2016-01-01)